Celon Pharma S.A. (WSE:CLN)
Poland · Delayed Price · Currency is PLN 20.75
-0.15 (-0.72%)
Aug 14, 2026, 5:00 PM CET
Celon Pharma Income Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 207.68 | 203.53 | 176.62 | 164.39 | 161.92 | 169.56 |
Other Revenue | 46.73 | 38.68 | 28.93 | 50.27 | 31.97 | 26.53 |
| 254.41 | 242.21 | 205.55 | 214.66 | 193.89 | 196.09 | |
Revenue Growth | 17.96% | 17.83% | -4.25% | 10.72% | -1.12% | 24.54% |
Cost of Revenue | 65.34 | 67.93 | 63.17 | 66.82 | 66.46 | 61.72 |
Gross Profit | 189.07 | 174.28 | 142.38 | 147.85 | 127.42 | 134.37 |
Selling, General & Admin | 139.58 | 135.06 | 120.04 | 111.12 | 107.7 | 90.11 |
Other Operating Expenses | 17.47 | 17.95 | 21.98 | 15.06 | 13.52 | 13.5 |
Operating Expenses | 201.2 | 199.3 | 195.31 | 176.2 | 165.32 | 144.96 |
Operating Income | -12.13 | -25.02 | -52.94 | -28.35 | -37.9 | -10.59 |
Interest Expense | -1.6 | -1.59 | -2.47 | -2.66 | -1.67 | -1.55 |
Interest & Investment Income | 0.48 | 0.5 | 0.16 | 0.37 | 1.85 | 0.08 |
Earnings From Equity Investments | -31.98 | -34.11 | -5.55 | - | - | - |
Currency Exchange Gain (Loss) | -0.49 | -0.02 | -0.4 | 0.03 | -0.4 | -2.59 |
Other Non Operating Income (Expenses) | 169.54 | 1.12 | 5.7 | 9.53 | 1.11 | -0.57 |
EBT Excluding Unusual Items | 123.83 | -59.12 | -55.49 | -21.08 | -37.01 | -15.22 |
Gain (Loss) on Sale of Assets | 0.05 | 0.15 | 0.68 | 1.11 | 0.56 | 0.13 |
Asset Writedown | - | - | 15.45 | - | - | - |
Pretax Income | 123.88 | -58.97 | -39.37 | -19.97 | -36.45 | -15.09 |
Income Tax Expense | 15.56 | 20.4 | -4.92 | 8.16 | 2.83 | -3.48 |
Net Income | 108.32 | -79.36 | -34.45 | -28.12 | -39.28 | -11.61 |
Net Income to Common | 108.32 | -79.36 | -34.45 | -28.12 | -39.28 | -11.61 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 53 | 53 | 54 | 51 | 51 | 47 |
Shares Outstanding (Diluted) | 53 | 53 | 54 | 51 | 51 | 47 |
Shares Change | -2.29% | -1.35% | 5.48% | 0.04% | 9.32% | 3.74% |
EPS (Basic) | 2.04 | -1.49 | -0.64 | -0.55 | -0.77 | -0.25 |
EPS (Diluted) | 2.04 | -1.49 | -0.64 | -0.55 | -0.77 | -0.25 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -34.61 | -30.58 | -34.13 | -41.13 | -38.61 | 2.6 |
Free Cash Flow Per Share | -0.65 | -0.58 | -0.63 | -0.81 | -0.76 | 0.06 |
Dividend Per Share | - | - | - | 0.080 | 0.090 | 0.290 |
Dividend Growth | - | - | - | -11.11% | -68.97% | 314.29% |
Gross Margin | 74.32% | 71.95% | 69.27% | 68.87% | 65.72% | 68.53% |
Operating Margin | -4.77% | -10.33% | -25.75% | -13.21% | -19.55% | -5.40% |
Profit Margin | 42.58% | -32.77% | -16.76% | -13.10% | -20.26% | -5.92% |
Free Cash Flow Margin | -13.60% | -12.63% | -16.61% | -19.16% | -19.91% | 1.33% |
EBITDA | 19.16 | 10.12 | -14.26 | 8.63 | -2.57 | 27.84 |
EBITDA Margin | 7.53% | 4.18% | -6.94% | 4.02% | -1.33% | 14.20% |
D&A For EBITDA | 31.28 | 35.14 | 38.68 | 36.99 | 35.33 | 38.43 |
EBIT | -12.13 | -25.02 | -52.94 | -28.35 | -37.9 | -10.59 |
EBIT Margin | -4.77% | -10.33% | -25.75% | -13.21% | -19.55% | -5.40% |
Effective Tax Rate | 12.56% | - | - | - | - | - |
Revenue as Reported | 256.87 | 244.34 | 207.19 | 216.57 | 194.59 | 199.11 |